Now more than ever, market access and health economics teams are faced with serious questions about the health equities of their drugs. Getting a drug into market is just the beginning: if your drug requires post-marketing surveillance or has been struggling with insurance adoption, patient access may run up against script rejections or patient reversals, resulting in overly high copays. These issues can cause coverage gaps and reputational hazards with far higher costs than preventative monitoring. 

These all too common come down to factors a drug manufacturer cannot control for but must have a handle on to succeed: the social determinants of health, the differences of demography and income that determine whether remarkable new drugs raise the tide of public health for all or widen inequities. 

PurpleLab solutions are custom built to analyze and address these challenges. With PurpleLab’s Social Determinants of Health Scan, any patient dataset can be overlapped in minutes to identify the number of records in your data. PurpleLab can also append social determinant data. Within one business day of the request, PurpleLab can confirm how many within your patient dataset have one, any, or all of the specific traits. This enables data science teams to assess how PurpleLab data can build upon patient profiles in your system and unlock health equity insights before they become a headline. 

To get started, simply fill out the form from the link below and we will contact you. From there, share the dataset you’d like PurpleLab to measure for SDOH and we will overlap the dataset and provide counts within one business day. PurpleLab SDOH is available to augment external datasets, or bundled with analysis of the rejections and reversals for a particular drug by date or prescribing physician.



Recommended Articles

COVID-19 has brought us past the tipping point on the issue of health inequity. No doubt, health disparities linked to social determinants of health (SDOH) – such as race, gender, age, ethnicity, income and education level) – have existed since the dawn of the U.S. healthcare system.

Life sciences companies would do both well and good to take advantage of the latest tools and platforms to understand the drivers of health inequity so that they can continue to root it out…

HCP segmentation can be a powerful tool for life sciences companies to target their best sales prospects—but historical data will only get you so far. Data that only looks back can be misleading, and a point-in-time snapshot can make it impossible to tell the difference between HCPs whose volumes are trending down and those who […]